MyStocks

MEMBER'S LOGINX

Remember Username
Keep me signed in

(Please do not use this option on a public machine)

Home
Research It
DISHMAN PHARMACEUTICALS & CHEMICALS LTD. (pharmaceuticals)
DISHMAN PHARMACEUTICALS & CHEMICALS LTD. Financial Data

Dishman Pharma Fact Sheet (DHPH)

Mail
Print
FaceBook
Twitter
Linked In
WhatsApp

Here is the latest financial fact sheet of Dishman Pharma. For more details, see the Dishman Pharma quarterly results and Dishman Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

DISHMAN PHARMA Price History

Price	Rs	301.1
Mkt Cap	Rs m	48,588
Vol	'000	460.5
P/E	X	25.1
P/CF	X	17.3
EPS (TTM)	Rs	12.0

% ch	%	2.9
No. of shares	m	161.39
% ch week	%	3.5
% ch 1-mth	%	-2.4
% ch 12-mth	%	96.4
52 week H/L	Rs	346.3/127.6

(As on May 29, 2017 (Close))

» Best Performing pharmaceuticals Stocks

1d 1w 1m 3m 6m 1y 3y 5y Max

* Results Consolidated

EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

DISHMAN PHARMA Financials

No. of Mths Year Ending	12 Mar-12*	12 Mar-13*	12 Mar-14*	12 Mar-15*	12 Mar-16*	5-Yr Chart Click to enlarge

DISHMAN PHARMA EQUITY SHARE DATA
High	Rs	107	122	107	183	374
Low	Rs	35	42	39	83	129
Sales per share (Unadj.)	Rs	139.3	157.7	171.7	196.9	197.8
Earnings per share (Unadj.)	Rs	7.0	12.4	13.5	14.8	21.2
Diluted earnings per share	Rs	3.5	6.2	6.8	7.4	10.6
Cash flow per share (Unadj.)	Rs	16.5	22.8	27.0	33.5	34.7
Dividends per share (Unadj.)	Rs	1.20	1.20	1.20	2.00	2.00
Adj. dividends per share	Rs	0.60	0.60	0.60	1.00	1.00
Dividend yield (eoy)	%	1.7	1.5	1.6	1.5	0.8
Book value per share (Unadj.)	Rs	115.3	128.2	146.4	153.4	179.9
Adj. book value per share	Rs	57.7	64.1	73.2	76.7	89.9
Shares outstanding (eoy)	m	80.69	80.69	80.69	80.69	80.69
Bonus/Rights/Conversions		-	-	-	-	-
Price / Sales ratio	x	0.5	0.5	0.4	0.7	1.3
Avg P/E ratio	x	10.1	6.6	5.4	8.9	11.9
P/CF ratio (eoy)	x	4.3	3.6	2.7	4.0	7.2
Price / Book Value ratio	x	0.6	0.6	0.5	0.9	1.4
Dividend payout	%	17.1	9.7	8.9	13.5	9.4
Avg Mkt Cap	Rs m	5,729	6,617	5,902	10,691	20,306
No. of employees	`000	1.0	1.1	0.9	0.9	0.8
Total wages/salary	Rs m	2,941	3,509	4,123	4,232	5,355
Avg. sales/employee	Rs Th	11,541.3	12,059.0	14,848.0	18,430.9	19,252.7
Avg. wages/employee	Rs Th	3,019.6	3,326.2	4,419.4	4,909.6	6,459.5
Avg. net profit/employee	Rs Th	582.8	950.6	1,171.2	1,389.9	2,064.1

DISHMAN PHARMA INCOME DATA
Net Sales	Rs m	11,241	12,722	13,853	15,887	15,961
Other income	Rs m	129	178	249	869	265
Total revenues	Rs m	11,370	12,900	14,102	16,757	16,226
Gross profit	Rs m	2,245	2,901	3,321	3,128	4,103
Depreciation	Rs m	765	838	1,086	1,507	1,091
Interest	Rs m	729	788	921	897	944
Profit before tax	Rs m	879	1,453	1,564	1,593	2,334
Minority Interest	Rs m	0	0	0	0	0
Prior Period Items	Rs m	0	0	0	0	1
Extraordinary Inc (Exp)	Rs m	0	0	0	0	0
Tax	Rs m	312	450	471	394	624
Profit after tax	Rs m	568	1,003	1,093	1,198	1,711
Gross profit margin	%	20.0	22.8	24.0	19.7	25.7
Effective tax rate	%	35.4	31.0	30.1	24.8	26.7
Net profit margin	%	5.0	7.9	7.9	7.5	10.7

DISHMAN PHARMA BALANCE SHEET DATA
Current assets	Rs m	6,239	6,733	8,245	10,135	11,018
Current liabilities	Rs m	6,547	7,127	9,028	11,048	9,517
Net working cap to sales	%	-2.7	-3.1	-5.7	-5.7	9.4
Current ratio	x	1.0	0.9	0.9	0.9	1.2
Inventory Days	Days	87	97	112	103	110
Debtors Days	Days	61	21	38	50	35
Net fixed assets	Rs m	14,391	14,579	15,717	15,827	16,304
Share capital	Rs m	161	161	161	161	161
"Free" reserves	Rs m	8,225	9,051	10,031	11,167	12,907
Net worth	Rs m	9,307	10,345	11,813	12,378	14,516
Long term debt	Rs m	5,121	4,336	4,121	3,302	4,189
Total assets	Rs m	22,490	22,911	26,277	28,089	29,805
Interest coverage	x	2.2	2.8	2.7	2.8	3.5
Debt to equity ratio	x	0.6	0.4	0.3	0.3	0.3
Sales to assets ratio	x	0.5	0.6	0.5	0.6	0.5
Return on assets	%	5.8	7.8	7.7	7.5	8.9
Return on equity	%	6.1	9.7	9.3	9.7	11.8
Return on capital	%	11.1	15.3	15.6	15.9	17.5
Exports to sales	%	30.3	28.3	27.8	22.6	24.8
Imports to sales	%	7.2	4.7	6.3	5.6	3.7
Exports (fob)	Rs m	3,404	3,595	3,855	3,598	3,956
Imports (cif)	Rs m	806	599	869	891	596
Fx inflow	Rs m	3,974	4,210	3,966	4,576	4,952
Fx outflow	Rs m	905	695	954	974	697
Net fx	Rs m	3,069	3,515	3,011	3,601	4,255

DISHMAN PHARMA CASH FLOW
From Operations	Rs m	1,536	1,651	3,445	2,937	2,786
From Investments	Rs m	-1,040	-1,173	-2,568	-1,581	-1,529
From Financial Activity	Rs m	-680	-502	-741	-1,420	-941
Net Cashflow	Rs m	-185	-23	136	-64	316

* Results Consolidated

Source: Company Annual Reports, Regulatory Filings, Equitymaster

» Historical quarterly results for dishman pharmaceuticals & chemicals ltd.

Share Holding

Indian Promoters	61.4%
Foreign collaborators	0.0%
Indian inst/Mut Fund	3.7%
FIIs	12.7%
ADR/GDR	0.0%
Free float	22.1%
Shareholders	46,261
Pledged promoter(s) holding	35.8%

Today's Market

Sensex Ends 146 Points Lower; IT and Power Stocks Drag(Closing)

Indian share markets witnessed selling pressure during closing hours and ended their trading session marginally lower.Sectoral indices ended on a mixed note with realty stocks.

Views on news

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

Eris Lifesciences Limited (IPO)

Jun 15, 2017

Exposure to high margin specialty products offers promising growth prospects.

More Views on News

Most Popular

The RCom Bankruptcy: 5 Lessons for Smallcap Investors(Profit Hunter)

Feb 7, 2019

Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

How We Pick the Most Profitable Stocks from the Portfolios of Super Investors(The 5 Minute Wrapup)

Feb 8, 2019

This is the trick to following super investors and not losing money.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
Add To MyStocks

DISHMAN PHARMA - FDC LTD. COMPARISON

Compare Company With Charts

COMPARE DISHMAN PHARMA WITH

MARKET STATS

ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

FREE NEWSLETTERS

PREMIUM PRODUCTS

QUICK LINKS

APPS

FOLLOW

Follow @Equitymaster

Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Testimonials